Gene test could help doctors pick best Pre-Surgery breast cancer treatment
NCT ID NCT03749421
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a gene test called Prosigna can help doctors choose the best treatment for women with a common type of breast cancer (HR+/HER2-) before surgery. About 60 women will have their treatment decisions recorded before and after the test results. The goal is to see if the test changes what treatment is recommended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prosigna PAM-50 gene test
What this could lead to
If successful, this could show that a gene test helps personalize breast cancer treatment before surgery, potentially improving outcomes.
What could go wrong
This is a small, early study (60 people) that only measures if doctors change their minds, not if patients actually do better. The test may not improve survival or reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States